79
Participants
Start Date
March 19, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
September 30, 2024
CM-24 and Nivolumab - Dose Escalation
Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors
CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
Nivolumab and Nal-IRI/5-FU/LV - Expansion
Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
Barbara Ann Karmanos Cancer Institute, Detroit
The University of Texas M.D. Anderson Cancer Center, Houston
University of Colorado, Aurora
HonorHealth Research Institute, Scottsdale
Yale University, New Haven
Rambam Health Care Campus, Haifa
Sheba Medical Center, Ramat Gan
Hospital Clinic Barcelona, Barcelona
NEXT Oncology Barcelona, Barcelona
Vall d' Hebron Institute of Oncology (VHIO), Barcelona
Clinica Universidad de Navarra, Madrid
Hospital 12 Octubre, Madrid
Hospital General Universitario Gregorio Maranon, Madrid
Hospital South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC, Madrid
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz, Madrid
Clinica Universidad de Navarra - Pamplona, Pamplona
NEXT Oncology Madrid, Pozuelo de Alarcón
Hospital Quiron Salud Valencia, Valencia
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Famewave Ltd.
INDUSTRY